Skip to Content

Generic Aveed Availability

Aveed is a brand name of testosterone, approved by the FDA in the following formulation(s):

AVEED (testosterone undecanoate - injectable;intramuscular)

  • Manufacturer: ENDO PHARMS INC
    Approval date: March 5, 2014
    Strength(s): 750MG/3ML (250MG/ML) [RLD]

Has a generic version of Aveed been approved?

No. There is currently no therapeutically equivalent version of Aveed available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Aveed. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels
    Patent 7,718,640
    Issued: May 18, 2010
    Inventor(s): Hubler; Doris & Fricke; Sabine & Ingwersen; Jan-Peter & Kuhnz; Wilhelm
    Assignee(s): Bayer-Schering Pharma AG
    The present invention relates to pharmaceutical compositions, formulated for injectable administration, which comprises a testosterone ester, in particularly testosterone undecanoate, in a vehicle comprising castor oil and a co-solvent. Upon injecting the compositions according to a particular administration scheme, reliable levels of testosterone in serum in the normal physiological range is achieved for a long period. This allows for the use of the compositions in hormone replacement therapy and male contraception without concomitant monitoring of testosterone levels in serum by a physician.
    Patent expiration dates:
    • March 14, 2027
      ✓ 
      Drug product
  • Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels
    Patent 8,338,395
    Issued: December 25, 2012
    Inventor(s): Hubler; Doris & Fricke; Sabine & Ingwersen; Jan-Peter & Kuhnz; Wilheim
    Assignee(s): Bayer Intellectual Property GmbH
    Described are methods for providing prolonged physiologically acceptable steady state serum testosterone levels in a patient deficient in endogenous testosterone levels, methods for male contraception and methods for treating a disease or symptom associated with deficient endogenous levels of testosterone in a man, by intramuscularly administering testosterone esters in a vehicle.
    Patent expiration dates:
    • February 27, 2026
      ✓ 
      Patent use: TESTOSTERONE REPLACEMENT THERAPY IN ADULT MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE; PRIMARY HYPOGONADISM (CONGENITAL OR ACQUIRED); HYPOGONADOTROPIC HYPOGONADISM (CONGENITAL OR ACQUIRED).

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • March 5, 2017 - NEW PRODUCT

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide